Daré Bioscience patents lopinavir-ritonavir insert for HPV clearance
Daré Bioscience has secured a new US patent covering pharmaceutical compositions of lopinavir and ritonavir formulated for topical application, strengthening the intellectual property position of its lead women's health programme, DARE-HPV. The patent, issued by the US Patent and Trademark Office on 14 July 2026 and licensed from Douglas Pharmaceuticals Limited, is expected to provide protection into at least 2039.
DARE-HPV is a fixed-dose soft gel vaginal insert combining the two protease inhibitors, which are best known as antiretroviral agents in HIV treatment. Daré is repurposing them to target persistent high-risk HPV infection, exploiting their antiviral mechanism in a localised, self-administered format. The company estimates that around six million women in the United States experience high-risk HPV infection each year, and it points out that no pharmacological treatment has so far received FDA approval for the indication.
Phase 2 progress and funding
The programme is currently in a randomised, placebo-controlled, double-blind Phase 2 study enrolling approximately 100 women with confirmed persistent high-risk HPV infection. The trial compares lower and higher doses of DARE-HPV against placebo over a treatment course of up to 21 days, with HPV clearance at three months post-treatment as the primary endpoint. Topline results are expected in 2027.
Development costs are being partially offset by approximately $10 million in non-dilutive funding awarded by the Advanced Research Projects Agency for Health (ARPA-H) through its Sprint for Women's Health initiative, alongside a $2 million grant from the National Institute of Allergy and Infectious Diseases. The combination of federal backing and an expanded patent estate reduces some of the financing risk typical for small-cap clinical-stage biotechs, though Daré still flagged reliance on additional milestone-based ARPA-H disbursements in its forward-looking disclosures.
President and chief executive Sabrina Martucci Johnson said the new patent "adds another important layer to the foundation we are building around DARE-HPV at a particularly exciting point in the program's development," describing the approach as offering a "localized, self-administered, non-surgical" alternative to current management strategies.
Market context and regulatory read-across
The absence of an approved pharmacological treatment for HPV infection represents a genuine gap in infectious disease management. Current clinical practice relies on monitoring and, where cervical lesions progress, surgical procedures such as loop excision. An approved drug capable of clearing persistent high-risk HPV before neoplastic progression could shift management toward earlier intervention and reduce downstream referrals for colposcopy and excision.
Daré intends to pursue approval under the FDA's 505(b)(2) pathway, which allows applicants to rely in part on published data for previously approved active ingredients, potentially shortening development timelines relative to a full new drug application. Lopinavir and ritonavir both have established safety profiles from long-term HIV use, which may ease the regulatory case on tolerability, though the topical gynaecological indication and the specific formulation will still require the full clinical evidence package the Phase 2 is designed to generate.
The women's health therapeutics space has attracted growing attention from both venture and government funders following years of underinvestment, and ARPA-H's involvement signals federal appetite for innovation in the area. Daré remains a small-cap operator, however, and investors will be closely watching 2027 topline data as the pivotal near-term catalyst for the programme's future.